Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-26, Stock:LLY, The news for the past five days is as follows:
2018-06-19: NEWS1: Daily Dividend Report: SBUX, LLY, USB, CL, IEX.NEWS2: Daily Dividend Report: SBUX, LLY, USB, CL, IEX.NEWS3: Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis.NEWS4: Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis.NEWS5: Snag This Bargain Even Cheaper Than SVP Skovronsky Did.NEWS6: Snag This Bargain Even Cheaper Than SVP Skovronsky Did.NEWS7: Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?.NEWS8: Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis.
2018-06-20: NEWS1: How Johnson & Johnson’s Valuation Compares.NEWS2: Regeneron Is Expected to Witness a Modest Revenue Rise in 2018.NEWS3: LLY vs. NVO: Which Stock Should Value Investors Buy Now?.NEWS4: NYSE Pharma And Biotech Dividend Stock Picks.
2018-06-21: NEWS1: Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study.NEWS2: Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study.NEWS3: Novo Nordisk&apos;s (NVO) Oral Ozempic Positive in Diabetes Study.NEWS4: Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities.
2018-06-22: NEWS1: U.S. District Court rules in favor of Lilly's Alimta patent.NEWS2: U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit.NEWS3: Merck (MRK) Stock Up So Far This Year on Keytruda Strength.NEWS4: Merck (MRK) Stock Up So Far This Year on Keytruda Strength.NEWS5: Incyte (INCY) Announces Positive Results on Jakafi for GVHD.NEWS6: Incyte (INCY) Announces Positive Results on Jakafi for GVHD.NEWS7: Lilly Completes Acquisition of ARMO BioSciences.
2018-06-25: NEWS1: Merck (MRK) Presents New Data from Januvia Diabetes Studies.NEWS2: Merck (MRK) Presents New Data from Januvia Diabetes Studies.NEWS3: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS4: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS5: Lilly Wins Favorable Ruling From U.S. Court in Alimta Row.NEWS6: Lilly's Jardiance meets main goal of two diabetes trials.NEWS7: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS8: Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes.NEWS9: First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes.NEWS10: Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache.NEWS11: Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C.NEWS12: Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C.NEWS13: Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint.NEWS14: Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint.NEWS15: Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts.NEWS16: Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts.

Answer: Decrease